US Patent Issued to HARBOUR BioMed (Shanghai) on Sept. 30 for "CLDN18.2-targeting antibody, bispecific antibody and use thereof" (Chinese Inventors)

ALEXANDRIA, Va., Sept. 30 -- United States Patent no. 12,428,479, issued on Sept. 30, was assigned to HARBOUR BioMed (Shanghai) Co. Ltd (Shanghai).

"CLDN18.2-targeting antibody, bispecific antibody and use thereof" was invented by Ming-Jin Jheng (Shanghai), Yongqiang Wang (Shanghai), Yun Zhang (Shanghai), Chuchu Zhao (Shanghai), Yunxing Yang (Shanghai), Fei Chen (Shanghai), Beibei Qin (Shanghai), Yuetao Wu (Shanghai) and Yi Ding (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention discloses CLDN18.2-targeting antibodies, bispecific antibodies and use thereof. The CLDN18.2-targeting antibody is a single-domain heavy-chain antibody that has high affinity for tumor cells endogenously e...